Cargando…

Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors. Ranging from Pan Ligands to Combined A1/A2B Partial Agonists

The amino-3,5-dicyanopyridine derivatives belong to an intriguing series of adenosine receptor (AR) ligands that has been developed by both academic researchers and industry. Indeed, the studies carried out to date underline the versatility of the dicyanopyridine scaffold to obtain AR ligands with n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catarzi, Daniela, Varano, Flavia, Varani, Katia, Vincenzi, Fabrizio, Pasquini, Silvia, Dal Ben, Diego, Volpini, Rosaria, Colotta, Vittoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958422/ https://www.ncbi.nlm.nih.gov/pubmed/31652622 http://dx.doi.org/10.3390/ph12040159

Ejemplares similares

4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives
por: Catarzi, Daniela, et al.
Publicado: (2022)

Piperazine- and Piperidine-Containing Thiazolo[5,4-d]pyrimidine Derivatives as New Potent and Selective Adenosine A(2A) Receptor Inverse Agonists
por: Varano, Flavia, et al.
Publicado: (2020)

Special Issue “Adenosine Receptors as Attractive Targets in Human Diseases”
por: Catarzi, Daniela, et al.
Publicado: (2021)

Inhibition of A(2A) Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455
por: Gessi, Stefania, et al.
Publicado: (2017)

The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A(1) and A(2A) receptor affinity and selectivity profiles
por: Squarcialupi, Lucia, et al.
Publicado: (2017)

Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives with High Affinity for Both the Adenosine A(1) and A(2A) Receptors, and Efficacy in Animal Models of Depression
por: Varano, Flavia, et al.
Publicado: (2021)

A(1) Adenosine Receptor Partial Agonists and Allosteric Modulators: Advancing Toward the Clinic?
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

“Dual Anta-Inhibitors” of the A(2A) Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies
por: Spinaci, Andrea, et al.
Publicado: (2023)

Adenosine and Inflammation: Here, There and Everywhere
por: Pasquini, Silvia, et al.
Publicado: (2021)

Pharmacological Characterization of P626, a Novel Dual Adenosine A(2A)/A(2B) Receptor Antagonist, on Synaptic Plasticity and during an Ischemic-like Insult in CA1 Rat Hippocampus
por: Venturini, Martina, et al.
Publicado: (2023)

Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

Design, synthesis and evaluation of amino-3,5-dicyanopyridines and thieno[2,3-b]pyridines as ligands of adenosine A(1) receptors for the potential treatment of epilepsy
por: Nkomba, Gaofenngwe, et al.
Publicado: (2022)

Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications
por: Pasquini, Silvia, et al.
Publicado: (2022)

Non-Nucleoside Agonists of the Adenosine Receptors: An Overview
por: Dal Ben, Diego, et al.
Publicado: (2019)

Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets
por: Pasquini, Silvia, et al.
Publicado: (2022)

Anxiolytic properties of A(1) adenosine receptor PAMs
por: Vincenzi, Fabrizio, et al.
Publicado: (2016)

Pharmacology of Adenosine Receptors: Recent Advancements
por: Vincenzi, Fabrizio, et al.
Publicado: (2023)

A(3) Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma
por: Vincenzi, Fabrizio, et al.
Publicado: (2021)

Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A(2B) adenosine receptor
por: Dal Ben, Diego, et al.
Publicado: (2013)

An Open Question: Is the A(2A) Adenosine Receptor a Novel Target for Alzheimer’s Disease Treatment?
por: Merighi, Stefania, et al.
Publicado: (2021)

A(2A) Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer’s Disease
por: Gessi, Stefania, et al.
Publicado: (2021)

A(2A) Adenosine Receptor: A Possible Therapeutic Target for Alzheimer’s Disease by Regulating NLRP3 Inflammasome Activity?
por: Merighi, Stefania, et al.
Publicado: (2022)

The Detrimental Action of Adenosine on Glutamate-Induced Cytotoxicity in PC12 Cells Can Be Shifted towards a Neuroprotective Role through A(1)AR Positive Allosteric Modulation
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

Caffeine for Prevention of Alzheimer’s Disease: Is the A(2A) Adenosine Receptor Its Target?
por: Merighi, Stefania, et al.
Publicado: (2023)

Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases Therapy
por: Fernandez, Mercedes, et al.
Publicado: (2023)

Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields
por: Varani, Katia, et al.
Publicado: (2017)

Role and Function of A(2A) and A(3) Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis
por: Ravani, Annalisa, et al.
Publicado: (2017)

Site-selective generation of lanthanoid binding sites on proteins using 4-fluoro-2,6-dicyanopyridine
por: Mekkattu Tharayil, Sreelakshmi, et al.
Publicado: (2022)

Adenosine Receptors as Neuroinflammation Modulators: Role of A(1) Agonists and A(2A) Antagonists
por: Martí Navia, Aleix, et al.
Publicado: (2020)

Pathophysiological Role and Medicinal Chemistry of A(2A) Adenosine Receptor Antagonists in Alzheimer’s Disease
por: Merighi, Stefania, et al.
Publicado: (2022)

A(2A) adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus
por: Bortoluzzi, Alessandra, et al.
Publicado: (2016)

The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A(3) Receptor Agonist, in a Rat Model of Colitis
por: Antonioli, Luca, et al.
Publicado: (2020)

A(2A )and A(3 )adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release
por: Varani, Katia, et al.
Publicado: (2011)

The Anti-Tumor Effect of A(3) Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells
por: Vincenzi, Fabrizio, et al.
Publicado: (2012)

A(2A) adenosine receptors are involved in the reparative response of tendon cells to pulsed electromagnetic fields
por: Colombini, Alessandra, et al.
Publicado: (2020)

Pulsed Electromagnetic Fields Stimulate HIF-1α-Independent VEGF Release in 1321N1 Human Astrocytes Protecting Neuron-like SH-SY5Y Cells from Oxygen-Glucose Deprivation
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

Pulsed Electromagnetic Field Stimulation in Osteogenesis and Chondrogenesis: Signaling Pathways and Therapeutic Implications
por: Varani, Katia, et al.
Publicado: (2021)

A(3) Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity
por: Spinaci, Andrea, et al.
Publicado: (2022)

Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition
por: Papa, Alessandro, et al.
Publicado: (2022)

Adenosine and lymphocyte regulation
por: Gessi, Stefania, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ehgamoi162lk7s4ng59tln5v9p